Tscan: Tracking down novel T cell targets

Tscan is finding novel TCR-antigen pairs with its peptidome screening platform

Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities.

"Most targets have been discovered in a one-off fashion, notably by Steve Rosenberg’s lab at the NCI," Tscan Therapeutics Inc. CEO David Southwell told BioCentury. "The barrier has been that there hasn’t been a high-throughput, whole-genome way to discover targets."

The company spun out of

Read the full 686 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers